Rep. Dingell on GPIA recommendations
The Michigan Democrat called "predictably and critically flawed" the recommendations for correcting the generic drug industry by an independent "blue ribbon" committee established by the Generic Pharmaceutical Industry Association. Although the advisory committee developed several "positive" recommendations, Dingell was not satisfied with the panel's proposals for dealing with scofflaw companies.
You may also be interested in...
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
CDRH director Jeff Shuren says the US agency’s device center has been tallying up lessons learned from the COVID-19 pandemic.
The market for devices to monitor and treat sleep apnea and its complications is set to grow by 7.3% annually in the next three years, with the US market expanding by 7.6% per year, according to the Meddevicetracker Dashboard.